Last $0.02 USD
Change Today -0.001 / -4.00%
Volume 511.3K
BHRT On Other Exchanges
As of 3:56 PM 09/22/14 All times are local (Market data is delayed by at least 15 minutes).

bioheart inc (BHRT) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/6/14 - $0.08
52 Week Low
12/12/13 - $0.0063
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BIOHEART INC (BHRT)

Related News

No related news articles were found.

bioheart inc (BHRT) Related Businessweek News

No Related Businessweek News Found

bioheart inc (BHRT) Details

Bioheart, Inc., a development stage biotechnology company, focuses on the discovery, development, and commercialization of autologous cell therapies for the treatment of chronic and acute heart damage, and degenerative diseases. Its lead product candidate is MyoCell, a clinical muscle-derived cell therapy that has completed Phase II-a study and populates regions of scar tissue within a patient’s heart with new living cells for improving cardiac function in chronic heart failure patients. The company also develops MyoCell SDF-1, an autologous cell therapy treatment for severe chronic damage to the heart and cells modified to express angiogenic factors; AdipoCell, an adipose cell therapy treatment for the management of progressive heart failure; and MyoCath, a disposable endoventricular catheter used for the delivery of biologic solutions to the myocardium. In addition, its preclinical stage product candidates include MyoCath II, which provides multidirectional cell injection, as well as is used for the delivery of biologic solutions to the myocardium. Bioheart, Inc. was founded in 1999 and is headquartered in Sunrise, Florida.

4 Employees
Last Reported Date: 08/1/14
Founded in 1999

bioheart inc (BHRT) Top Compensated Officers

Chief Executive Officer, President, Principal...
Total Annual Compensation: $766.7K
Chief Scientific Officer, Director and Member...
Total Annual Compensation: $284.2K
Compensation as of Fiscal Year 2013.

bioheart inc (BHRT) Key Developments

Bioheart Announces Opening of Laboratory and Clinic in South Africa

Bioheart, Inc. announced the opening the laboratory and clinic in South Africa. The facilities in South Africa opening will be able to provide cell therapies in the clinic as well as cell culture expansion and cryopreservation to local patients. Bioheart can multiply and preserve an individual's cells in sub-zero temperatures for future treatments as required. Bioheart's partnership will establish a critical relationship with the South African government and the joint venture will work closely with the Ministry of Health to make Bioheart protocols part of the standard of care for patients in South Africa and neighboring countries. Bioheart has provided the necessary training and expertise to transfer Bioheart therapies to the new facility. Bioheart will assume 49% ownership of the new entity. Dr. Walter Bell and his team will offer these therapies to the more than 51 million people living in South Africa as well as being a premier site for medical tourism.

Bioheart, Inc. Announces Earnings Results for the Year to Date Ended June 30, 2014

Bioheart, Inc. announced earnings results for the year to date ended June 30, 2014. For the period, the company product revenues are up from $24,321 to $819,606 comparing year to date of 2013 to year date of 2014. The revenues recognized to date are related to sales of MyoCath, patient treatments, AdipoCell systems and related supplies, and cell culturing and banking services. The company's net income increased to $226,034, as compared to a net loss of $1,269,231 in year to date of 2013, primarily resulting from gain on settlement of debt. The company has continued to take steps to streamline operational costs, decreasing its net cash used in operating activities by 54% from $1,095,000 in year to date of 2013 down to $507,000 in year to date of 2014.

Bioheart, Inc. Announces Combination Stem Cell Treatment

Bioheart, Inc. announced that it has completed the combination stem cell treatment with Magnum Cell Therapies (Magnum) in Honduras. A patient with congestive heart failure has been treated with a combination of AdipoCell(TM) or adipose derived stem cells and MyoCell(R) or muscle derived stem cells. AdipoCell may help to promote angiogenesis or new blood vessel formation in ischemic tissue while MyoCell may help to promote myogenesis or new muscle formation. The cells were delivered directly into the damaged areas of the heart using the MyoCath(R) Catheter.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BHRT:US $0.02 USD -0.001

BHRT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Aastrom Biosciences Inc $2.62 USD -0.12
Athersys Inc $1.41 USD 0.00
Cytomedix Inc $0.42 USD -0.02
Cytori Therapeutics Inc $0.87 USD -0.1304
International Stem Cell Corp $0.09 USD -0.001
View Industry Companies

Industry Analysis


Industry Average

Valuation BHRT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 13.2x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOHEART INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at